SpyGlass Pharma Acquires AVS in $13M Deal to Secure IOL Manufacturing

Vertical integration of a critical component supplier before a Phase 3 readout is a calculated de-risking move, and SpyGlass Pharma's $13 million acquisition of Advanced Vision Science, Inc. (AVS) from Santen Pharmaceutical illustrates the logic precisely. For procurement and supply chain leads at clinical-stage device-pharma hybrids, the transaction sets a reference point for how to convert a contract manufacturing dependency into a controlled, scalable asset before commercial pressure arrives.

AVS, a California-based manufacturer operating under ISO 13485 certification with dual registration by the US FDA and Japan's Ministry of Health, Labour and Welfare, is the current supplier of the intraocular lens (IOL) used in SpyGlass Pharma's two ongoing Phase 3 registrational trials evaluating the BIM-IOL System. Bringing that supplier in-house eliminates a single-source vulnerability at exactly the moment when manufacturing scalability becomes a regulatory and commercial prerequisite.

The acquisition structure preserves existing third-party supply relationships rather than disrupting them. AVS will continue as exclusive IOL manufacturer and supplier to Santen for the Japanese market, and will maintain its licensing arrangement with Bausch + Lomb covering the glistening-free hydrophobic acrylic lens material used in the enVista® line. That continuity limits integration risk and keeps the facility's utilisation rates commercially supported during the transition period.

Beyond supply security, SpyGlass Pharma gains manufacturing capability for premium lens formats, specifically toric and extended depth-of-focus IOLs, which the company intends to evaluate as future carriers for its drug delivery pad technology. The BIM-IOL System's current monofocal configuration addresses the majority of glaucoma and ocular hypertension patients presenting with cataracts, but the expanded lens portfolio opens a development pathway for patient subgroups who require corrective optics alongside drug delivery. For QA and regulatory leads, that expansion implies future 510(k) or PMA supplement activity as new lens-drug combination configurations enter the pipeline.

AVS brings a manufacturing history dating to 1975 and an established quality system, factors that reduce the remediation burden typically associated with post-acquisition site integration. The facility's existing regulatory standing with both US and Japanese authorities means SpyGlass Pharma inherits a compliant manufacturing base rather than one requiring re-qualification before it can support a commercial launch.

The pace of Phase 3 execution will determine how quickly the integrated manufacturing capacity needs to scale to commercial volumes, making trial progress the near-term checkpoint for supply chain planners tracking this acquisition.

Source: SpyGlass Pharma, Inc. via GlobeNewswire, October 1, 2026.